Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

219.03 +1.17 (+0.54%)
Delayed Quote Updated: 10:47 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
News headline image
Semiconductors Fail A Key Support Level - And More ↗
It has been 2 years and 2 months since the ETF for Semiconductors SMH has traded below the 50-week moving average. 
Via Talk Markets
Topics ETFs
News headline image
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
News headline image
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? ↗
The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder. 
Via Stocktwits
News headline image
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst ↗
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
News headline image
The Inside Sectors Of The Economy Flash Warning ↗
Zooming out to the weekly chart of TLT, we see a double bottom in play from the lows in October 2023 and January 2025. 
Via Talk Markets
Topics Commodities ETFs Economy
News headline image
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? ↗
Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results. 
Via Stocktwits
News headline image
Biotech Stocks Had A Good Week Despite Crosscurrents ↗
It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Do The Major Sector ETFs Love High Flying Stocks? ↗
The major sector ETFs remain muted. Nothing screams wildly bullish or horribly bearish in the weekly charts. 
Via Talk Markets
Topics Cryptocurrencies ETFs
News headline image
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing ↗
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
News headline image
Price Action Disputes Most Macro Narratives ↗
Do you believe the economy is heading towards inflation? What about a recession? Are gold prices sending a warning? Read on for the answer. 
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
Can Biotech Stocks Survive The Precarious Macro? ↗
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
News headline image
Compare/Contrast - Year Of The Yin Wood Snake 1965 And 2025 ↗
The Federal debt in 1965 was $322.3 billion. In 2025 it is at $36.24 trillion. The unemployment rate was 5.2%. Now it is at 4.1%. 
Via Talk Markets
Topics ETFs
News headline image
Small- To Mid-Cap Biotech Trades Poised For Gains ↗
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
DeepSeek Is Not New - The Rotation Away From Tech Is ↗
The technical aspect of DeepSeek is not new. The reaction to it though, is new. 
Via Talk Markets
Topics Commodities
News headline image
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens ↗
The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects. 
Via Stocktwits
News headline image
Healthcare And Biotech Stocks Lag The Market Again ↗
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
News headline image
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025. 
Via MarketBeat
Topics ETFs Economy
News headline image
Major Sector ETFs January Trend Trade is Here ↗
Transportation IYT chart is incredible. The price action Friday showed the attempt to take out the January trend trade range and then failed. 
Via Talk Markets
Topics ETFs
News headline image
Inflation, Soft Landing, January Trend Trade Working Out ↗
Sugar, as shown in the weekly chart, has broken down under the 200-WMA for the first time since December 2020. However, it is holding the August 2024 low. 
Via Talk Markets
Topics Commodities ETFs Economy
News headline image
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ ↗
Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. 
Via Benzinga
News headline image
The Major Sector ETFs Remain Technically Intact ↗
As long as XRT holds 78.00, it’s back where it broke out from after a massive consolidation last year. 
Via Talk Markets
Topics Cryptocurrencies ETFs
News headline image
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗
The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Happy New Year Or Is It For The Major Sector ETFs? ↗
Russell 2000 IWM, has a few key points of support to hold. $217 is one. The 50-week moving average at around $212.45 is another. 
Via Talk Markets
Topics ETFs
News headline image
Healthcare And Biotech Stocks Continue Their Slide ↗
Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Major Sector ETFs - Buy This Dip? ↗
​​​​​​​As we ended this week, clearly Nasdaq held up better than pretty much everything else. 
Via Talk Markets
Topics Commodities ETFs
News headline image
The Major Sector ETFs Talk Turkey ↗
Retail XRT should hold the gap up it started this past week with. If that is the case, we anticipate a move higher for the coming week. 
Via Talk Markets
Topics Currencies/Forex ETFs
News headline image
Momentum Model For Trading SMID Biotech Stocks: Broad Rally Underway ↗
Biotech stocks are poised for a recovery in a seasonally strong period through January 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Major Sector ETFs - Retail Rallies ↗
What we waited for was a weekly close over 79.20, a level we have not seen since February 2022. 
Via Talk Markets
Topics Cryptocurrencies ETFs
News headline image
Is Biotech’s Bull Run Over? Examining Election Impacts
The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup. 
Via MarketBeat
Topics ETFs Government
News headline image
Cameco, Applied Digital, West Pharmaceutical And More On CNBC's 'Final Trades' ↗
On CNBC's "Halftime Report Final Trades," Tim Seymour of Seymour Asset Management picked Cameco Corporation. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.